Navigation Links
Phase 3 trials of two multi-kinase inhibitors against cancer

Sorafenib and stutent multi-kinase inhibitors against cancer is undergoing phase 3 trials// and these two drugs gained more appreciation in this years ASCO (American Society of Clinical Oncology) conference. This drug is gaining interest due to its multiple mechanism of action – known as Multi-kinase inhibitors. These drugs are in trial against different types of cancer and are found to be very effective. This two multi targeted oncology drug candidate is a small molecule named Sorafenib (Bay43-9006) and stutent (SU11248).

Sorafenib is produced by Onyx pharmaceuticals of California collaborating with Bayer pharmaceuticals of Connecticut and Stutent by Pfizer of New York city. Both these drugs are undergoing phase 3 trials.

Results of the study show that Sorafenib in advanced kidney cancer patients taking the drug lived twice as long as that placebo. Gleevec (imatinib) resistant gastrointestinal stromal tumors (GIST) were much less likely to progress in patients taking stutent versus those on placebo.

Both these drug act against tumor and its ability to recruit new blood vessels essential for growth and dissemination via multiple mechanisms. Sorafenib works by inhibiting the RAF/MEK/ERK pathway and, in parallel, impedes angiogenesis by inhibiting vascular endothelial growth factor-2 (VEGF-2) and platelet derived growth factor beta (PDGF- a). Stutent also has dual actions, killing VEGF and PDGF- á and a as well as FLT-3 and C-KIT.

Pfizer is developing more multi-targeted cancer drugs, such as small AG-013736 which has encouraging results in its phase 2 trials in kidney cancer.

Multi-targeted drug has also downsides of having side effects and allow less flexibility. But, so far there was no side effects reported in Sorafenib or stutent.


'"/>




Page: 1

Related medicine news :

1. SARS-Free Taiwan to Mark End Phase of Global Fight
2. Spray on contraceptive clears Phase I trial
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. Phase II trails of new HIV vaccine to be held in South Africa
5. FDA approves Phase 0 trial which tests experimental drugs on humans
6. Jalgaon: Third Phase Of Culling Operations Begin
7. Phase 1 Drug Trials on Humans to Be Made Public
8. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
9. Cadila to Commence Phase I Clinical Trials On ZYH2
10. iGATE Completes Phase I Testing Of Meningitis Vaccine
11. ADHD Treatment -Phase 3 data on Lisdexamfetamine dimesylate Presented
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology: